'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.
India is ready, after battling the pandemic for two years, to travel once again.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
Ahmedabad was the first stop in the PM's three city tour today, to personally review the vaccine development and manufacturing process in the country.
Dr V K Paul, Member (Health) Niti Aayog, who also chairs the national expert group on COVID-19 vaccine administration, said the government attaches 'great importance to this offer of partnership from a very special friend to this nation'.
Director of the US National Institute of Allergy and Infectious Diseases, Dr Fauci said that India made the "incorrect assumption" that they were finished with COVID-19.
The modalities of COVID-19 vaccine delivery, distribution and administration were discussed during the meeting.
From the middle of next week, shops, personal care, gyms and churches can reopen as part of a bolstered three-tiered system. As part of the restrictions, people will be expected to continue to work from home if they live in a Tier 1 region; in Tier 2, alcohol can only be served with a meal; and in Tier 3, all forms of hospitality except takeaways will have to close.
In a tweet, Prime Minister Narendra Modi said India is deeply honoured to be a 'long-trusted' partner in meeting the healthcare needs of the global community and that supplies of the vaccines to several countries will commence on Wednesday, and more will follow in the days ahead.
Some states have flagged the shortage of vaccines and expressed their inability to start vaccination of people above 18 years from Saturday
Out of the 447 adverse events following immunisation, only 3 required hospitalisation.
Senior Congress leader Manish Tewari and Union Health Minister Harsh Vardhan sparred on Twitter on Saturday with the Opposition leader raising questions over the emergency use approval given to the indigenously developed vaccine Covaxin and the Bharatiya Janata Party leader hitting back alleging that Tewari was only passionate about spreading rumours.
'We are hoping by March, the government allows us to export and give it to the private market.'
The company has set an affordable ceiling price of USD 3 (around Rs 225) per dose, it added.
"The country wide vaccination exercise is being exponentially expanded to include those above 60 years of age and those above 45 years with co-morbidities, from March 1.
The 'terrible' surge of the coronavirus cases in India has severely impacted COVAX's vaccine supply in the second quarter of this year to the extent that there will be a shortfall of 190 million doses by the end of June, according to a joint statement by the WHO, UNICEF, GAVI and CEPI.
Poonawalla, during an interaction with Odisha Chief Minister Naveen Patnaik through a video conference, expressed optimism that the COVID-19 vaccine could be ready by October-November this year and the next phase of the trial can start in mid-August in India. According to a press note released by the CMO, Poonawalla has informed that the Oxford University vaccine has shown promising results in the first phase trial.
Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.
AstraZeneca on Wednesday announced that it had filed separate patent infringement actions in the United States District Court, Delaware, against seven generic drug manufacturers, which have submitted abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) seeking marketing authorisation for Crestor.
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
The UK government has ordered 100 million doses of the Oxford vaccine once it is ready for rollout and the doses are being manufactured before it has been shown to be successful in order to save time once it clears all the regulatory stages.
Addressing a virtual Downing Street press conference, Boris Johnson acknowledged the divided views on lifting all lockdown restrictions to declare that his update does not imply that the pandemic "is over".
"The president pledged America's steadfast ongoing support for the people of India, who have been impacted by the recent surge in the COVID-19 cases," White House Press Secretary Jen Psaki told reporters at her daily news conference.
Speaking during Prime Minister Narendra Modis video conference meeting with chief ministers of eight states which have reported high COVID-19 cases, Thackeray said the PM or Union Home Minister Amit Shah should convene a meeting of all parties to tell them about the seriousness of the situation.
The first dry run of the vaccination drive took place across 125 districts covering all States/UTs on January 2. The dry run was also conducted to familiarise the state, district, block, and hospital-level officers on all aspects of the COVID-19 rollout.
Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and 'killer T-cells', a senior source from the trial was quoted by The Daily Telegraph as saying.
'The Union government has discouraged state and local governments from imposing restrictions on their own.' 'That advice should be withdrawn,' asserts Mihir S Sharma.
Early data from its vaccine candidate 'mRNA-1273' showed it produced protective antibodies in a group of eight healthy volunteers, Moderna said. The other closely watched COVID-19 vaccine is the one being developed by scientists at Oxford University.
Millions of people across the country stayed indoors on March 22, 2020 in an unprecedented and overwhelming response to Prime Minister Narendra Modi's appeal for the nationwide curfew. People used to come out briefly at 5 pm to show their gratitude to healthcare and other essential service providers with sounds of bells, conches and claps.
865 million Indian adults require vaccination.
COVAX, 'the global COVID vaccine equity scheme', has so far delivered 65 million doses to 124 countries and economies but it is dependent on countries and manufacturers honouring their commitments.
Health practitioners who have been vaccinated against coronavirus or have administered the shots to others took part, sharing their first-hand experiences.
During the webinar, 'COVID-19: Vaccination and Potential Return to Normalcy - If and When', Dr Hotez, an internationally-recognised physician-scientist in neglected tropical diseases and vaccine development, said that the COVID-19 vaccine rollout is "India's gift' to the world in combating the virus.
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.
Laws governing compensation in case of adverse side effects for Covaxin and Covishield may differ in accordance with the kind of approvals given, say legal experts.
'Your body will be able to deal with Omicron at any time, but it depends (on when) if you are vaccinated.'
Paul noted that "three to four months from now, there will be other vaccines and the stockpile will be even bigger. "And more acceleration can be brought about in the vaccination programme," Paul added.
Some critics contend that Japan's rush to secure supplies is driven largely by a political desire to show the world it is fully committed to hosting the Games.
At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances